“Lyophilization in Pharmaceuticals market set to grow to $9.2bn by 2024” says new Visiongain report

28 March 2019
Pharma

Visiongain has published a new pharma report Lyophilization in Pharmaceuticals Market Forecast 2019-2029: Food Processing and Packaging, Pharmaceutical and Biotechnology, Medical Application, Industrial-scale, Pilot-scale, Laboratory-scale, Tray-style Freeze Dryers, Manifold Freeze Dryers, Shell Freeze Dryers, Loading & Unloading Systems, Controlling & Monitoring Systems, Vacuum Systems, Clean-In-Place (CIP) Systems, Drying Chambers, Freeze Drying Trays & Shelves, Manifolds, Other Accessories.

The global lyophilization in pharmaceuticals market is estimated to have reached $5.6bn in 2018. The pharmaceutical and biotechnology segment held 33% of the lyophilization market in 2018.

Pharmaceutical and biotechnology drugs are often highly sensitive and complex molecules that can be negatively affected by external factors such as sunlight, oxygen, pH and others. Leaving marketers and manufacturers looking for an innovative way to preserve and protect these difficult-to-handle substances, lyophilization offers a highly efficient and suitable technique to meet the needs for handling the complexities of constituents during pharmaceutical manufacturing.

The lead analyst commented that "Lyophilization in pharmaceuticals and biotechnology is growing at a rapid pace due to the high safety and sterility offered by freeze-dried injectables, mainly in the case of unstable proteins that are highly susceptible to chemical and physical disintegration and changes.

The lyophilization market includes a large number of small and medium-sized companies and stable innovative activity. End-users have the opportunity to choose from a number of suppliers. External forces have a significant effect on this industry, such as government involvement regulatory agencies and reimbursement policies. On a global level, we can expect growth in this market, especially in the emerging economies."

Leading companies featured in this report include Azbil Corporation, Biophama process Systems, Inc., GEA Group, Labconco Corporation, Millrock Technology, Inc.and others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes RNA Analysis/Transcriptomics Market Report 2020-2030

Rising preference for personalised medicine in developed as well developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase RNA analysis/transcriptomics market concentration over the forecast period. In order to increase the reliability and success rate of the drug production process.

30 November 2020

Read

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever